1.0	hemodynamic	effects.
0.0	ARDS	and
1.0	either	iNO
0.0	with	iNO
1.0	using	standard
0.0	to	improve
0.0	on	currently
0.0	for	iNO
1.0	consistent	end
0.0	in	the
1.0	conditions	associated
1.0	treatment	of
1.0	reporting	on
1.0	epoprostenol	(aEPO)
0.0	in	disease
0.0	of	these
1.0	estimated	mortality
0.0	of	either
1.0	relevant	studies
1.0	ALI	or
0.0	and	aerosolized
1.0	an	estimated
0.0	were	examined
0.0	aEPO	is
0.0	and	ALI.
0.0	were	included
0.0	on	changes
1.0	currently	available
1.0	devices	and
1.0	been	observed
0.0	to	use
1.0	observed	in
0.0	the	clinical
1.0	associated	with
1.0	application	of
0.0	the	safety
1.0	changes	in
0.0	of	inhaled
0.0	studies	addressing
1.0	injury	(ALI)
1.0	determine	the
1.0	end	points
0.0	and	standard
0.0	with	an
1.0	ventilator-free	days,
1.0	examined	for
1.0	modes	of
1.0	(iNO)	and
1.0	delivery	devices
0.0	the	article
1.0	This	article
1.0	overall	benefit
1.0	acute	lung
0.0	standard	modes
1.0	is	safe
0.0	in	patients
0.0	or	ARDS
1.0	(ARDS)	and
0.0	oxygenation	or
1.0	safety	and
1.0	respiratory	distress
1.0	survival,	ventilator-free
0.0	oxygenation	without
0.0	standard	delivery
0.0	to	the
1.0	prospective	randomized
0.0	in	oxygenation.
1.0	(aEPO)	in
1.0	(ALI)	are
1.0	disease	severity.
0.0	or	aEPO.
0.0	of	40â€“50%.
0.0	iNO	or
0.0	the	use
0.0	article	also
1.0	have	been
0.0	and	efficacy
0.0	to	determine
1.0	trials	were
0.0	clinical	application
0.0	article	reviews
0.0	or	attenuation
1.0	a	practicable
0.0	use	of
0.0	with	consistent
1.0	days,	or
1.0	The	use
1.0	randomized	controlled
1.0	points	using
0.0	for	changes
1.0	mortality	of
1.0	aerosolized	epoprostenol
0.0	and	acute
1.0	differences	have
0.0	in	oxygenation
1.0	In	addition,
1.0	syndrome	(ARDS)
1.0	data,	the
1.0	practicable	guide
1.0	patients	with
0.0	are	conditions
1.0	No	differences
1.0	can	help
0.0	studies	with
1.0	mechanical	ventilation
1.0	oxide	(iNO)
1.0	guide	to
1.0	benefit	with
1.0	transiently	improve
0.0	inhaled	nitric
0.0	use	in
1.0	hypoxemia	associated
1.0	available	data,
1.0	also	provides
1.0	controlled	trials
1.0	efficacy	of
1.0	lung	injury
1.0	help	to
1.0	reports	of
1.0	these	therapies.
0.0	the	overall
1.0	Further	studies
1.0	addressing	the
1.0	vasodilators	can
1.0	safe	to
0.0	of	aEPO
1.0	Seven	reports
1.0	distress	syndrome
1.0	Acute	respiratory
1.0	Nine	prospective
1.0	provides	a
1.0	Based	on
0.0	are	needed
0.0	with	ALI
0.0	or	clinical
0.0	in	survival,
0.0	inhaled	vasodilators
0.0	iNO	reporting
0.0	the	treatment
1.0	reviews	relevant
0.0	aEPO	were
1.0	included	for
1.0	nitric	oxide
1.0	without	hemodynamic
0.0	of	mechanical
0.0	improve	oxygenation.
0.0	or	aEPO
0.0	of	life-threatening
1.0	ventilation	are
0.0	to	transiently
0.0	clinical	outcomes.
1.0	life-threatening	hypoxemia
0.0	improve	oxygenation
1.0	attenuation	in
0.0	with	ARDS
1.0	needed	to
0.0	ARDS	to
1.0	addition,	the
